APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents and Insulin Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Hypoglycemic Agents and Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025193 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents and Insulin Injection Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents and Insulin Injection Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents and Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents and Insulin Injection Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents and Insulin Injection Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents and Insulin Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Hypoglycemic Agents and Insulin Injection include YZJ Group, Takeda Pharmaceuticals, Tonghua Dongbao Pharmaceutical, Sichuan Luye Pharma, Sanofi, Johnson & Johnson, Merck, The United Laboratories International Holdings and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Hypoglycemic Agents and Insulin Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Hypoglycemic Agents and Insulin Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Hypoglycemic Agents and Insulin Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Hypoglycemic Agents and Insulin Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Hypoglycemic Agents and Insulin Injection Segment by Company

YZJ Group

Takeda Pharmaceuticals

Tonghua Dongbao Pharmaceutical

Sichuan Luye Pharma

Sanofi

Johnson & Johnson

Merck

The United Laboratories International Holdings

Pfizer

Huadong Medicine

Gan and Lee Pharmaceuticals

AstraZeneca

Taisho Pharmaceutical

Servier Laboratories

Novo Nordisk

GlaxoSmithKline

Eli Lilly and Company

Chugai Pharmaceutical

Bristol Myers Squibb

Boehringer Ingelheim

Astellas

Oral Hypoglycemic Agents and Insulin Injection Segment by Type

Oral Hypoglycemic Agents

Insulin Injection

Oral Hypoglycemic Agents and Insulin Injection Segment by Application

E-commerce and Internet Medical Care

Offline Retail Pharmacy

Hospitals and Clinics

Oral Hypoglycemic Agents and Insulin Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents and Insulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents and Insulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents and Insulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Hypoglycemic Agents and Insulin Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Hypoglycemic Agents and Insulin Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Hypoglycemic Agents and Insulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Hypoglycemic Agents and Insulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Hypoglycemic Agents and Insulin Injection Industry Trends Table 2. Oral Hypoglycemic Agents and Insulin Injection Industry Drivers Table 3. Oral Hypoglycemic Agents and Insulin Injection Industry Opportunities and Challenges Table 4. Oral Hypoglycemic Agents and Insulin Injection Industry Restraints Table 5. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Manufacturers (M Units) & (2021-2026) Table 8. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Manufacturers Table 9. Global Oral Hypoglycemic Agents and Insulin Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oral Hypoglycemic Agents and Insulin Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Hypoglycemic Agents and Insulin Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers, Product Type & Application Table 13. Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Hypoglycemic Agents and Insulin Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Hypoglycemic Agents Table 17. Major Manufacturers of Insulin Injection Table 18. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 19. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 20. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 21. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2021-2026) Table 22. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2027-2032) Table 23. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type 2021 VS 2025 VS 2032 (M Units) Table 24. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (M Units) Table 25. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (M Units) Table 26. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2021-2026) Table 27. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of E-commerce and Internet Medical Care Table 29. Major Manufacturers of Offline Retail Pharmacy Table 30. Major Manufacturers of Hospitals and Clinics Table 31. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 32. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 33. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 34. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2021-2026) Table 35. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2027-2032) Table 36. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application 2021 VS 2025 VS 2032 (M Units) Table 37. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (M Units) Table 38. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (M Units) Table 39. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2021-2026) Table 40. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2027-2032) Table 41. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 42. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2026) & (M Units) Table 43. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Region (2021-2026) Table 44. Global Oral Hypoglycemic Agents and Insulin Injection Sales Forecasted by Region (2027-2032) & (M Units) Table 45. Global Oral Hypoglycemic Agents and Insulin Injection Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 47. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 48. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 49. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 50. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 51. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 52. Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 53. Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 54. Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 55. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 56. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 57. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 58. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2021-2026) Table 62. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2027-2032) Table 63. YZJ Group Company Information Table 64. YZJ Group Business Overview Table 65. YZJ Group Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. YZJ Group Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 67. YZJ Group Recent Development Table 68. Takeda Pharmaceuticals Company Information Table 69. Takeda Pharmaceuticals Business Overview Table 70. Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 72. Takeda Pharmaceuticals Recent Development Table 73. Tonghua Dongbao Pharmaceutical Company Information Table 74. Tonghua Dongbao Pharmaceutical Business Overview Table 75. Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 77. Tonghua Dongbao Pharmaceutical Recent Development Table 78. Sichuan Luye Pharma Company Information Table 79. Sichuan Luye Pharma Business Overview Table 80. Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 82. Sichuan Luye Pharma Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sanofi Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 87. Sanofi Recent Development Table 88. Johnson & Johnson Company Information Table 89. Johnson & Johnson Business Overview Table 90. Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 92. Johnson & Johnson Recent Development Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Merck Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 97. Merck Recent Development Table 98. The United Laboratories International Holdings Company Information Table 99. The United Laboratories International Holdings Business Overview Table 100. The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 102. The United Laboratories International Holdings Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Pfizer Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 107. Pfizer Recent Development Table 108. Huadong Medicine Company Information Table 109. Huadong Medicine Business Overview Table 110. Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 112. Huadong Medicine Recent Development Table 113. Gan and Lee Pharmaceuticals Company Information Table 114. Gan and Lee Pharmaceuticals Business Overview Table 115. Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 117. Gan and Lee Pharmaceuticals Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 122. AstraZeneca Recent Development Table 123. Taisho Pharmaceutical Company Information Table 124. Taisho Pharmaceutical Business Overview Table 125. Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 127. Taisho Pharmaceutical Recent Development Table 128. Servier Laboratories Company Information Table 129. Servier Laboratories Business Overview Table 130. Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 132. Servier Laboratories Recent Development Table 133. Novo Nordisk Company Information Table 134. Novo Nordisk Business Overview Table 135. Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 137. Novo Nordisk Recent Development Table 138. GlaxoSmithKline Company Information Table 139. GlaxoSmithKline Business Overview Table 140. GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 142. GlaxoSmithKline Recent Development Table 143. Eli Lilly and Company Company Information Table 144. Eli Lilly and Company Business Overview Table 145. Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 147. Eli Lilly and Company Recent Development Table 148. Chugai Pharmaceutical Company Information Table 149. Chugai Pharmaceutical Business Overview Table 150. Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 152. Chugai Pharmaceutical Recent Development Table 153. Bristol Myers Squibb Company Information Table 154. Bristol Myers Squibb Business Overview Table 155. Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 157. Bristol Myers Squibb Recent Development Table 158. Boehringer Ingelheim Company Information Table 159. Boehringer Ingelheim Business Overview Table 160. Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 162. Boehringer Ingelheim Recent Development Table 163. Astellas Company Information Table 164. Astellas Business Overview Table 165. Astellas Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Astellas Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 167. Astellas Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Oral Hypoglycemic Agents and Insulin Injection Distributors List Table 171. Oral Hypoglycemic Agents and Insulin Injection Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents and Insulin Injection Product Image Figure 2. Global Oral Hypoglycemic Agents and Insulin Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents and Insulin Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Hypoglycemic Agents and Insulin Injection Sales (2021-2032) & (M Units) Figure 5. Global Oral Hypoglycemic Agents and Insulin Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Hypoglycemic Agents Image Figure 9. Insulin Injection Image Figure 10. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 11. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2021-2032) Figure 13. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021 VS 2025 VS 2032) & (M Units) Figure 14. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2021-2032) Figure 16. E-commerce and Internet Medical Care Image Figure 17. Offline Retail Pharmacy Image Figure 18. Hospitals and Clinics Image Figure 19. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 20. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2021-2032) Figure 22. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021 VS 2025 VS 2032) & (M Units) Figure 23. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2021-2032) Figure 25. North America Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 26. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2032) Figure 27. U.S. Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 28. Canada Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 29. Mexico Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 30. Europe Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 31. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2032) Figure 32. Germany Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 33. France Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 34. U.K. Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 35. Italy Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 36. Netherlands Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 37. Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 38. Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2032) Figure 39. China Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 40. Japan Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 41. South Korea Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 42. Southeast Asia Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 43. India Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 44. Australia Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 45. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 46. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2032) Figure 47. Brazil Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 48. South Africa Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 49. Saudi Arabia Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 50. Turkey Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 51. Argentina Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 52. UAE Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 53. Egypt Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 54. Chile Oral Hypoglycemic Agents and Insulin Injection Sales and Growth Rate (2021-2032) & (M Units) Figure 55. Global Oral Hypoglycemic Agents and Insulin Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 58. North America Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 60. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Oral Hypoglycemic Agents and Insulin Injection Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Oral Hypoglycemic Agents and Insulin Injection Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Hypoglycemic Agents
  • Insulin Injection
Applications
  • E-commerce and Internet Medical Care
  • Offline Retail Pharmacy
  • Hospitals and Clinics
Companies covered
  • YZJ Group
  • Takeda Pharmaceuticals
  • Tonghua Dongbao Pharmaceutical
  • Sichuan Luye Pharma
  • Sanofi
  • Johnson & Johnson
  • Merck
  • The United Laboratories International Holdings
  • Pfizer
  • Huadong Medicine
  • Gan and Lee Pharmaceuticals
  • AstraZeneca
  • Taisho Pharmaceutical
  • Servier Laboratories
  • Novo Nordisk
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Chugai Pharmaceutical
  • Bristol Myers Squibb
  • Boehringer Ingelheim
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Hypoglycemic Agents and Insulin Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Hypoglycemic Agents and Insulin Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Hypoglycemic Agents and Insulin Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Hypoglycemic Agents and Insulin Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Hypoglycemic Agents and Insulin Injection Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents and Insulin Injection Industry Trends
  2. 2.2 Oral Hypoglycemic Agents and Insulin Injection Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents and Insulin Injection Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents and Insulin Injection Industry Restraints
3 Oral Hypoglycemic Agents and Insulin Injection Market by Manufacturers
  1. 3.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Hypoglycemic Agents and Insulin Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Hypoglycemic Agents and Insulin Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Hypoglycemic Agents and Insulin Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers, Product Type & Application
  7. 3.7 Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Hypoglycemic Agents and Insulin Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Hypoglycemic Agents and Insulin Injection Tier 1, Tier 2, and Tier 3
4 Oral Hypoglycemic Agents and Insulin Injection Market by Type
  1. 4.1 Oral Hypoglycemic Agents and Insulin Injection Type Introduction
  2. 4.1.1 Oral Hypoglycemic Agents
  3. 4.1.2 Insulin Injection
  4. 4.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type
  5. 4.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type
  9. 4.3.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2021-2032)
5 Oral Hypoglycemic Agents and Insulin Injection Market by Application
  1. 5.1 Oral Hypoglycemic Agents and Insulin Injection Application Introduction
  2. 5.1.1 E-commerce and Internet Medical Care
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 Hospitals and Clinics
  5. 5.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application
  6. 5.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application
  10. 5.3.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2021-2032)
6 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region
  1. 6.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region
  1. 7.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region
  2. 7.1.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032)
  8. 7.2.2 North America Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032)
  11. 7.3.2 Europe Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 YZJ Group
  2. 8.1.1 YZJ Group Company Information
  3. 8.1.2 YZJ Group Business Overview
  4. 8.1.3 YZJ Group Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 YZJ Group Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  6. 8.1.5 YZJ Group Recent Developments
  7. 8.2 Takeda Pharmaceuticals
  8. 8.2.1 Takeda Pharmaceuticals Company Information
  9. 8.2.2 Takeda Pharmaceuticals Business Overview
  10. 8.2.3 Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  12. 8.2.5 Takeda Pharmaceuticals Recent Developments
  13. 8.3 Tonghua Dongbao Pharmaceutical
  14. 8.3.1 Tonghua Dongbao Pharmaceutical Company Information
  15. 8.3.2 Tonghua Dongbao Pharmaceutical Business Overview
  16. 8.3.3 Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  18. 8.3.5 Tonghua Dongbao Pharmaceutical Recent Developments
  19. 8.4 Sichuan Luye Pharma
  20. 8.4.1 Sichuan Luye Pharma Company Information
  21. 8.4.2 Sichuan Luye Pharma Business Overview
  22. 8.4.3 Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  24. 8.4.5 Sichuan Luye Pharma Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 The United Laboratories International Holdings
  44. 8.8.1 The United Laboratories International Holdings Company Information
  45. 8.8.2 The United Laboratories International Holdings Business Overview
  46. 8.8.3 The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  48. 8.8.5 The United Laboratories International Holdings Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Huadong Medicine
  56. 8.10.1 Huadong Medicine Company Information
  57. 8.10.2 Huadong Medicine Business Overview
  58. 8.10.3 Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  60. 8.10.5 Huadong Medicine Recent Developments
  61. 8.11 Gan and Lee Pharmaceuticals
  62. 8.11.1 Gan and Lee Pharmaceuticals Company Information
  63. 8.11.2 Gan and Lee Pharmaceuticals Business Overview
  64. 8.11.3 Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  66. 8.11.5 Gan and Lee Pharmaceuticals Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 Taisho Pharmaceutical
  74. 8.13.1 Taisho Pharmaceutical Company Information
  75. 8.13.2 Taisho Pharmaceutical Business Overview
  76. 8.13.3 Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  78. 8.13.5 Taisho Pharmaceutical Recent Developments
  79. 8.14 Servier Laboratories
  80. 8.14.1 Servier Laboratories Company Information
  81. 8.14.2 Servier Laboratories Business Overview
  82. 8.14.3 Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  84. 8.14.5 Servier Laboratories Recent Developments
  85. 8.15 Novo Nordisk
  86. 8.15.1 Novo Nordisk Company Information
  87. 8.15.2 Novo Nordisk Business Overview
  88. 8.15.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  90. 8.15.5 Novo Nordisk Recent Developments
  91. 8.16 GlaxoSmithKline
  92. 8.16.1 GlaxoSmithKline Company Information
  93. 8.16.2 GlaxoSmithKline Business Overview
  94. 8.16.3 GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  96. 8.16.5 GlaxoSmithKline Recent Developments
  97. 8.17 Eli Lilly and Company
  98. 8.17.1 Eli Lilly and Company Company Information
  99. 8.17.2 Eli Lilly and Company Business Overview
  100. 8.17.3 Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  102. 8.17.5 Eli Lilly and Company Recent Developments
  103. 8.18 Chugai Pharmaceutical
  104. 8.18.1 Chugai Pharmaceutical Company Information
  105. 8.18.2 Chugai Pharmaceutical Business Overview
  106. 8.18.3 Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  108. 8.18.5 Chugai Pharmaceutical Recent Developments
  109. 8.19 Bristol Myers Squibb
  110. 8.19.1 Bristol Myers Squibb Company Information
  111. 8.19.2 Bristol Myers Squibb Business Overview
  112. 8.19.3 Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  114. 8.19.5 Bristol Myers Squibb Recent Developments
  115. 8.20 Boehringer Ingelheim
  116. 8.20.1 Boehringer Ingelheim Company Information
  117. 8.20.2 Boehringer Ingelheim Business Overview
  118. 8.20.3 Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  120. 8.20.5 Boehringer Ingelheim Recent Developments
  121. 8.21 Astellas
  122. 8.21.1 Astellas Company Information
  123. 8.21.2 Astellas Business Overview
  124. 8.21.3 Astellas Oral Hypoglycemic Agents and Insulin Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Astellas Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  126. 8.21.5 Astellas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Hypoglycemic Agents and Insulin Injection Value Chain Analysis
  2. 9.1.1 Oral Hypoglycemic Agents and Insulin Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Hypoglycemic Agents and Insulin Injection Production Mode & Process
  6. 9.2 Oral Hypoglycemic Agents and Insulin Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Hypoglycemic Agents and Insulin Injection Distributors
  9. 9.2.3 Oral Hypoglycemic Agents and Insulin Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst